Investors Split on Becton Dickinson After Guidance Cut

Overview

• Aristotle Atlantic disclosed it sold Becton, Dickinson and Company after a weak fiscal quarter led to reduced earnings and revenue guidance.
• The manager cited pressure from cuts to NIH-funded biosciences programs, anticipated tariff impacts, and skepticism about realizing full value from planned Biosciences and Diagnostic Solutions divestitures.
• By contrast, Hinde Group initiated a new long position in BDX as a special situation, its first new holding since 2022.
• Hinde highlighted leading market shares, a 54.7% gross margin and 25.0% operating margin, high returns on tangible capital, and stable demand for essential consumables.
• BDX reported fiscal Q4 2025 revenue up 7% to $5.9 billion (3.9% organic), and as of November 14 the shares closed at $193.04 with a $55.33 billion market cap, down 13.86% over 12 months.